An article published this year in “NANO RESEARCH” using our Cell
Cycle Analysis (PI / RNASE) solution, by our customers from Department of
Organic Chemistry, Faculty of ScienceUniversity of Málaga and Biosanitary
Institute of Granada (IBS. GRANADA) SAS-Universidad de Granada, Spain, in the study
of how Paclitaxel-loaded hollow-poly (4-vinylpyridine) nanoparticles enhance
drug chemotherapeutic efficacy in lung and breast cancer cell lines. Congrats
and Thanks.
Summary:
Paclitaxel (PTX), one of the most
effective cytotoxins for the treatment of breast and lung cancer, is limited by
its severe side effects and low tumor selectivity. In this work,
hollow-poly(4-vinylpyridine) (hollow-p4VP) nanoparticles (NPs) have been used
for the first time to generate PTX@p4VP NPs, employing a novel technique in
which a gold core in the center of the NP is further oxidized to produce the
hollow structure into which PTX molecules can be incorporated. The hollow-p4VP
NPs exhibit good physicochemical properties and displayed excellent
biocompatibility when tested on blood (no hemolysis) and cell cultures (no
cytotoxicity). Interestingly, PTX@p4VP NPs significantly increased PTX
cytotoxicity in human lung (A-549) and breast (MCF-7) cancer cells with a
significant reduction of PTX IC50 (from 5.9 to 3.6 nM in A-549 and from 13.75
to 4.71 nM in MCF-7). In addition, PTX@p4VP caused a decrease in volume of
A-549 and MCF-7 multicellular tumor spheroids (MTS), an in vitro system that
mimics in vivo tumors, in comparison to free PTX. This increased antitumoral
activity is accompanied by efficient cell internalization and increased
apoptosis, especially in lung cancer MTS. Our results offer the first evidence
that hollow-p4VP NPs can improve the antitumoral activity of PTX. This system
can be used as a new nanoplatform to overcome the limitations of current breast
and lung cancer treatments.
Reference:
Product link:
No comments:
Post a Comment